Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2010 Sep;42(3):180-4. doi: 10.4143/crt.2010.42.3.180. Epub 2010 Sep 30.
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
舒尼替尼治疗血液透析的转移性肾细胞癌患者的适宜剂量和方案尚未确定。我们回顾了延世大学医学院延世癌症中心接受舒尼替尼治疗的两名血液透析的转移性肾细胞癌患者。每次血液透析后（每周 3 或 4 次）间歇给予 50 毫克舒尼替尼。在报告时（2010 年 4 月），两例均为部分缓解。无进展生存期分别为 16 个月和 6 个月。两例患者均耐受治疗。
